Rahul G Argula

658 posts

Rahul G Argula banner
Rahul G Argula

Rahul G Argula

@RahulArgula

Husband, Dad, Crossword nerd, Classic Rock devotee, Politics junkie, Pulmonary/Critical care doc, Physiology buff, passionate about Pulmonary vascular disease.

Charleston, SC Joined Kasım 2017
1K Following350 Followers
Rahul G Argula
Rahul G Argula@RahulArgula·
@yreddyhf Agree. Great work! These patients (in our clinical practice) with low PVR are very fatigued, more SOB despite a low PVR. I also think this is an endophenotype within the SSc PAH population (due to high telangiectasia burden?). Paying close attention to the SVR is so important.
English
0
0
2
41
Yogesh Reddy
Yogesh Reddy@yreddyhf·
PVR is not everything in PAH and we need to think about ways to decrease RV work as sotatercept does through pulmonary vascular reverse remodeling. PAH Rx needs to continue to advance beyond vasodilators alone, with many parallels to how HFrEF Rx expanded after the 1980s.
English
4
0
4
317
Rahul G Argula retweeted
Yogesh Reddy
Yogesh Reddy@yreddyhf·
As we enter the sotatercept era and move beyond vasodilators alone for PAH, we find that roughly 10% get high output states from vasodilators that is missed on non-invasive testing and worsens RV work due to volume load despite marked PVR reduction. publications.ersnet.org/content/erj/ea…
Yogesh Reddy tweet media
English
2
9
31
1.8K
Ryan J Tedford MD
Ryan J Tedford MD@RyanTedfordMD·
🔥Excited for the Phase 2 CADENCE trial results of sotatercept in Cpc-PH (due to HFpEF) as a Late-Breaking Clinical Trial at #ACC26! Topline data already released: met primary endpoint with significant PVR reduction. Huge shoutout to the incredible team behind this—promising step forward for this challenging group! ⭐️ @mardigomberg @jeanlucvachiery @MUSC_Cardiology @AlessiaUrbinati
Ryan J Tedford MD tweet media
English
7
30
80
10.3K
Roberto J. Bernardo, MD, MS, ATSF 🇵🇪🇺🇸
Roberto J. Bernardo, MD, MS, ATSF 🇵🇪🇺🇸@rjbernardoMD·
@RahulArgula @SandeepSahayMD @yonsung97 @REstradaMD @RogerAlvarezDO @RFPMachado @heresi_gustavo @sonjabart @mardigomberg @ChaseStroudMD @LungTxptMD This may be purely anecdotal, but we’re noticing that the super responders start developing a worsening of PGI2 side effects, and that’s the main driver on cutting down on the dose (to control the PGI2 side effects). We’re not seeing telangiectasis or epistaxis yet, but ⏰ 👀
English
2
0
1
155
Rahul G Argula
Rahul G Argula@RahulArgula·
Had a great conversation about BMPR signal modulation from the guru himself @bmprii . Arguably, the most consequential and paradigm changing work that helps the right ventricles of PAH patients. Wait, where is @RyanTedfordMD ?
Rahul G Argula tweet media
English
1
1
17
1.2K
Rahul G Argula
Rahul G Argula@RahulArgula·
Amazing two days at PHA 2024. Felt the energy after connecting with the PH community. I’m so glad that the entire MUSC PVD team (except Denise :( )got to experience PHA this year. MUSC was well represented. Grateful for all the talented and hardworking people that I work with.
Rahul G Argula tweet mediaRahul G Argula tweet mediaRahul G Argula tweet mediaRahul G Argula tweet media
English
0
0
8
279
Rahul G Argula
Rahul G Argula@RahulArgula·
Great study! iNO consumes a significant amount of resources in health systems. Substitution of iNO with iEPO can translate into significant cost savings!
Jason N. Katz@JasonKatzMD

Really important study by @KamGhadimiMD and others @DukeHeartCenter. Amazing work. Must read! @ShashankSinhaMD @Carnicelli_Ant @seanvandiepen @RanLeeMD @criticalecho Inhaled Epo vs Nitric Oxide for RV Support After Major Cardiac Surgery | Circulation ahajournals.org/doi/10.1161/CI…

English
1
1
6
1.1K
Rahul G Argula
Rahul G Argula@RahulArgula·
@LucillaPiccari 😂😂 your article clearly cut across traditional academic boundaries....if one ignores the automated email spamming technology behind it, one should wear it like a badge of honor! #PHuelling the awareness!
English
1
0
1
116
Rahul G Argula
Rahul G Argula@RahulArgula·
If you are planning on attending ATS 2023 and have an interest in PH in the SSc patient, don't forget to register for my talk. See below for details. The registrations are limited, on a first come first serve basis (not my rules sorry) so don't wait for the last minute.
Rahul G Argula@RahulArgula

Interested in learning about pulmonary hypertension (PH) in Systemic sclerosis (SSc) ? Join me for a talk at #ATS2023 about the complex and overlapping phenotypes of PH in SSc & their Rx using case studies from our multi-disciplinary SSc program at MUSC. abstractsonline.com/pp8/#!/10703/s…

English
0
1
14
1.4K
cfbechara
cfbechara@cfbechara·
Very interesting diagram, will read article later for details, due to high HF patient population at HMH and HD patients we used to get consulted about AVF flow contribution to HF. Our cardiology colleagues used to take these patients to Cath lab and check cardiac pressures
Yevgeniy Brailovsky DO MSc FACC@YevgeniyBr

Great job @ewarnermd for leading the effort! We highlight importance of early recognition and management of HOHF and PH after the creation of AVF Are we missing an opportunity to reverse course? A call to action to raise awareness. @JeffIMchiefs @TJHeartFellows @JCardFail

English
1
0
6
2.5K
Rahul G Argula
Rahul G Argula@RahulArgula·
You will have to register to be able to attend the talk. Session details: MTE49- PHENOTYPING SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY HYPERTENSION
English
0
0
1
229
Rahul G Argula
Rahul G Argula@RahulArgula·
Interested in learning about pulmonary hypertension (PH) in Systemic sclerosis (SSc) ? Join me for a talk at #ATS2023 about the complex and overlapping phenotypes of PH in SSc & their Rx using case studies from our multi-disciplinary SSc program at MUSC. abstractsonline.com/pp8/#!/10703/s…
English
1
8
27
3.6K

Discover

@yreddyhf @Anjaliydv1706 @RyanTedfordMD @kurt_prins @sese_denise @AndrewJSauer @robmentz @MUSCCardFellows